{"filings":[{"id":68203,"accession_number":"0001437749-26-016724","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2026-05-13T20:10:24+00:00","items":["2.02","9.01"],"status":"ready","headline":"Talphera Q1 net loss $2.6M; NEPHRO CRRT study enrollment progressing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.6M ($0.04 per share) in Q1 2026, flat vs Q1 2025.","Cash and investments $21.1M as of March 31, 2026.","Combined R&D and SG&A expenses $3.9M, up from $2.9M YoY due to higher Niyad development costs.","NEPHRO CRRT study enrollment exceeded 50% milestone; completion expected in 2026.","Closed $4.1M third tranche of private placement upon hitting 35-patient enrollment milestone."],"consensus_eps_estimate":-0.0714,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103939,"accession_number":"0001437749-26-009299","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Talphera reports Q4 net loss $3.8M; NEPHRO CRRT study 50% enrolled, all 12 sites active","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $20.4M at Dec 31, 2025; net loss $3.8M ($0.06 per share) vs $1.9M ($0.07) in Q4 2024.","NEPHRO CRRT registrational study reached 35 of 70 patients (50% enrollment); all 12 sites now enrolling.","Closed $4.1M tranche of private placement upon achieving 35-patient milestone; total financing proceeds $1.6M in October 2025.","Combined R&D and SG&A expenses $3.5M in Q4 2025 vs $3.0M in Q4 2024; increase driven by Niyad development costs.","2026 cash operating expense guidance $17M-$18M, up from ~$13M in 2025, including finalizing CRRT trial and CMC/validation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103938,"accession_number":"0001437749-26-008318","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Talphera closes $4.1M third tranche of private placement, issuing shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Third closing on March 13, 2026: 639,931 shares at $0.586/share and pre-funded warrants for 6,399,316 shares at $0.585 each.","Pre-funded warrants exercisable immediately, exercise price $0.001, unlimited term.","Aggregate gross proceeds of approximately $4.1 million from the third closing.","Securities sold under Section 4(a)(2) and Regulation D; not registered under Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103937,"accession_number":"0001437749-26-008217","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Talphera receives Nasdaq bid price deficiency notice; 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on March 11, 2026 for non-compliance with minimum bid price of $1.00 per share.","Deficiency exists after 30 consecutive business days below $1.00; stock currently trades on Nasdaq Capital Market.","Company has 180 calendar days, until September 7, 2026, to regain compliance by closing at $1.00 for 10 consecutive days.","If not compliant by deadline, Talphera may seek a second 180-day period if it meets other listing standards.","Company intends to monitor bid price and evaluate options, including reverse stock split if necessary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120215,"accession_number":"0001437749-25-034446","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Talphera Q3 net loss $4.4M; cash $21.3M; Niyad study on track for H1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.4M ($0.11/sh) vs $3.4M ($0.13/sh) in Q3 2024.","Cash and investments $21.3M at Sept 30; sufficient through potential Niyad PMA approval late 2026.","Closed $17M first tranche financing led by CorMedix (CRMD); second tranche up to $29M conditional.","Five of nine NEPHRO trial sites activated; enrollment completion expected H1 2026.","Reduced 2025 cash operating expense guidance to $14-15M from $16-17M."],"consensus_eps_estimate":-0.1428,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":28000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120214,"accession_number":"0001437749-25-031731","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Talphera stockholders approve reverse stock split; company regained Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders elected Vincent J. Angotti, Stephen J. Hoffman, and Abhinav Jain as Class II directors.","Approved reverse stock split (1:10-1:30) to regain compliance; company already regained compliance on Oct 20, 2025.","Ratified BPM LLP as independent registered public accounting firm for FY2025.","Approved amendments to 2020 Equity Incentive Plan and 2011 Employee Stock Purchase Plan.","Advisory say-on-pay approved; future vote to be held annually."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120213,"accession_number":"0001437749-25-031468","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"Talphera raises ~$1.6M in final private placement tranches; regains Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 1,023,890 shares at $0.586/share and pre-funded warrants for 1,706,484 shares at $0.585/warrant.","Pre-funded warrants exercisable at $0.001/share with unlimited term; gross proceeds ~$1.6M.","Nasdaq notified Talphera on Oct 20, 2025 that it regained bid price compliance (closing bid ≥$1.00 for 10 consecutive days ending Oct 17, 2025).","Second and third closings of private placement occurred after certain purchasers waived conditions on Oct 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120212,"accession_number":"0001437749-25-031162","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2025-10-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Talphera appoints Joseph Todisco (CorMedix CEO) to board; grants RSUs and options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph Todisco appointed Class III director and compensation committee member effective Oct 14, 2025.","Todisco is CEO of CorMedix; appointment per Sept 2025 securities purchase agreement.","Granted 6,397 RSUs and options for 38,381 shares at $1.11, vesting in three equal annual installments.","CorMedix retains right to designate one board member while holding >=25% of shares from private placement.","CorMedix gets 60-day exclusive right to negotiate acquisition of Talphera after Niyad NEPHRO CRRT results, until Dec 31, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136789,"accession_number":"0001437749-25-028787","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Talphera raises ~$17M in private placement with CorMedix; second closing tied to NEPHRO CRRT","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 25,036,360 shares at $0.55/share and pre-funded warrants for 5,845,455 shares; gross proceeds ~$17M.","Second closing of ~$12M contingent on achieving primary endpoint in NEPHRO CRRT study and VWAP >= $0.6875.","CorMedix gets board designation right if it holds >=25% of first-closing shares; 60-day exclusive negotiation right after positive NEPHRO CRRT results.","Registration rights agreement requires Talphera to file resale registration statement within 15 days after each closing.","Right of first negotiation terminates if NEPHRO CRRT study is terminated before primary endpoint or by Dec 31, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136788,"accession_number":"0001437749-25-026938","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Talphera Q2 net loss $3.5M ($0.10/sh); NEPHRO study enrollment accelerates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["15 patients enrolled in NEPHRO registrational study; on track for completion by end of 2025, PMA submission Q1 2026.","Cash and equivalents $6.8M at June 30, 2025; closed $4.9M first tranche of $14.8M financing.","Net loss from continuing ops $3.5M vs $3.8M YoY; combined R&D/SG&A expenses $3.7M vs $4.3M.","Reduced 2025 cash operating expense guidance to $16M-$17M from prior $17M-$19M."],"consensus_eps_estimate":-0.102,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":27000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154016,"accession_number":"0001437749-25-019574","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Talphera gets 180-day extension to regain Nasdaq $1.00 bid price compliance through Dec 1, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice granting second 180-day compliance period until December 1, 2025 for minimum bid price requirement.","Common stock transferred to Nasdaq Capital Market from Global Select Market on May 30, 2025; trades under symbol TLPH.","To regain compliance, closing bid price must be at least $1.00 per share for 10 consecutive business days.","Company intends to consider a reverse stock split if necessary; warns no assurance of regaining compliance.","If not compliant by December 1, 2025, Nasdaq will delist; company may appeal to Nasdaq Hearings Panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154015,"accession_number":"0001437749-25-016840","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Talphera Q1 2025 net loss narrows to $0.10/share; NEPHRO study reduced to 70 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $2.7M vs $4.0M YoY; diluted EPS loss $0.10 vs $0.16.","Cash $5.4M at March 31; adjusted to $9.8M after $4.4M net proceeds from April financing tranche.","FDA agreed to reduce NEPHRO CRRT study from 166 to 70 patients; primary endpoint powered at 90%.","Three new clinical sites activated in 2025; five more expected by mid-year for total of 13.","2025 cash operating expense guidance $17-19M, including completing registration trial by year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":27000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154014,"accession_number":"0001437749-25-010729","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Talphera raises $4.9M in first closing of private placement; additional closings contingent on trial enrollment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$4.9M from first closing: 3,405,118 shares and pre-funded warrants for 4,999,316 shares at $0.586/share.","Second closing of ~$4.9M triggered by enrollment of ≥17 patients in Niyad NEPHRO CRRT study and VWAP ≥$0.7325.","Third closing of ~$4.9M triggered by enrollment of ≥35 patients in same study and VWAP ≥$0.7325.","Pre-funded warrants have $0.001 exercise price, unlimited term, and are exercisable immediately at each closing.","Registration rights agreement filed; executive officers and directors subject to 90-day lock-up after effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172647,"accession_number":"0001437749-25-010190","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Talphera reports Q4 2024 net loss $1.9M; FDA cuts NEPHRO study size to 70 patients","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA agreed to reduce NEPHRO CRRT study from 166 to 70 patients; study completion targeted by end of 2025.","Cash and investments of $8.9M at Dec 31, 2024; additional $14.8M private placement financing announced.","Q4 2024 net loss from continuing operations $1.9M ($0.07 per share) vs $4.5M ($0.25) in Q4 2023.","Combined R&D and SG&A expenses decreased to $3.0M in Q4 2024 from $4.6M in Q4 2023.","2025 cash operating expense guidance of $18M-$19M, includes costs to complete NEPHRO study."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":27000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189659,"accession_number":"0001437749-24-037242","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-12-11T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Talphera receives Nasdaq notice for non-compliance with $1.00 minimum bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Dec 6, 2024 for failure to maintain minimum bid price of $1.00 for 30 consecutive business days.","Must regain compliance by June 4, 2025; closing bid must be at least $1.00 for ten consecutive business days.","If not cured, Company may seek an additional 180-day compliance period if it meets other Nasdaq Capital Market standards.","Company states it will monitor closing bid price and evaluate options including reverse stock split to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189658,"accession_number":"0001437749-24-036376","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-11-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Talphera receives Nasdaq deficiency notice for stockholders' equity below $10M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity as of Sept 30, 2024 was $9.641M, below Nasdaq's $10M minimum for Global Market.","Company must submit a compliance plan by Jan 13, 2025; Nasdaq may grant up to 180-day extension.","If plan not accepted, Nasdaq will initiate delisting; Talphera can appeal to a hearings panel.","Talphera intends to submit a compliance plan but no assurance that Nasdaq will accept it.","Notice has no immediate effect on listing; common stock continues trading on Nasdaq Global Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189657,"accession_number":"0001437749-24-034907","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Talphera Q3 net loss widens to $3.4M; NEPHRO CRRT study enrollment underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.4M ($0.13/share) vs $1.4M ($0.08) in Q3 2023; cash and investments $11.1M.","Five clinical sites screening for NEPHRO CRRT study; two more expected in Q4; study completion anticipated in 2025.","Combined R&D and SG&A expenses $3.7M, up from $3.4M, driven by NEPHRO study costs.","DSUVIA divestment classified as discontinued operations; no related expenses in Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189656,"accession_number":"0001437749-24-030380","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Talphera extends deadline for second closing under securities purchase agreement to June 30, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment dated September 30, 2024 with Nantahala Management-affiliated purchasers.","Second closing deadline extended from earlier date to June 30, 2025.","If Company completes an equity financing before second closing, purchasers released from obligation to buy additional shares.","No change to other terms of original January 2024 securities purchase agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206145,"accession_number":"0001437749-24-026815","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Talphera Q2 net loss $3.8M; CMO Palmer retiring Oct 1, succeeded by Dr. Aslam","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.8M ($0.15 loss per share) vs $4.4M ($0.40 loss) in Q2 2023; cash $14.0M.","NEPHRO CRRT registrational study screening initiated; enrolling 166 patients at up to 14 U.S. sites.","Pamela Palmer, co-founder and CMO, to retire Oct 1; Dr. Shakil Aslam (current CDO) to become CMO.","Combined R&D and SG&A expenses rose to $4.3M from $4.2M year-over-year; no DSUVIA expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223195,"accession_number":"0001437749-24-021108","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Talphera stockholders elect directors, approve auditor and equity plans at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Adrian Adams and Jill Broadfoot elected as Class I directors with ~5.2M votes each.","BPM LLP ratified as independent auditor for FY 2024; 9.1M for, 0.3M against.","Advisory say-on-pay approved: 4.6M for, 0.6M against, 0.4M abstain.","Amended and restated 2020 Equity Incentive Plan and 2011 ESPP approved with >4.6M for.","Total shares represented: 9.56M of 16.99M outstanding (56.3% quorum)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223194,"accession_number":"0001437749-24-016626","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Talphera reports Q1 2024 net loss $4.0M; NEPHRO study enrollment delayed, guidance revised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $4.0M vs income $0.1M in Q1 2023; basic EPS -$0.16.","Cash and investments $18.6M as of March 31, 2024.","NEPHRO CRRT study enrollment delayed; top-line data guidance (by Sept 30) to be revised.","Dr. Shakil Aslam appointed Chief Development Officer effective May 20, 2024.","Combined R&D and SG&A expenses decreased to $4.2M from $5.3M year-over-year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223193,"accession_number":"0001437749-24-012568","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-04-19T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Talphera sets 2024 annual meeting for June 24; announces proposal deadlines","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for June 24, 2024; record date is April 26, 2024.","Rule 14a-8 stockholder proposals must be received by April 23, 2024.","Director nominations under bylaws due by April 29, 2024.","Universal proxy notice for proxy solicitations required by April 25, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242687,"accession_number":"0001437749-24-006817","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Talphera Q4 net loss $4.5M; cash $9.4M; Niyad study enrollment imminent; $26M committed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops of $4.5M ($0.25/sh) vs $5.9M ($1.00/sh) in Q4 2022; revenues $0.3M.","Cash and investments $9.4M at Dec 31, 2023; senior debt fully repaid in Q2 2023.","Jan 2024: $26M committed capital — $8M DSUVIA royalty monetization with Xoma + $18M equity from two investors.","First patient enrollment in NEPHRO CRRT registrational study expected Q1 2024; PMA submission targeted by end 2024.","Company rebranded from AcelRx to Talphera in Jan 2024; now trades as TLPH on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242686,"accession_number":"0001437749-24-006219","cik":1427925,"company_name":"TALPHERA, INC.","ticker":"TLPH","form_type":"8-K","filed_at":"2024-03-01T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Talphera reduces board from 10 to 7; three directors resign; regains Nasdaq bid price compliance","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Directors Richard Afable, Howard Rosen, and Pamela Palmer resigned effective Feb 26-28, 2024, no disagreements.","Board size reduced from ten to seven directors; committees reconstituted with continuing members.","Nasdaq notified Talphera on Feb 27 that it regained compliance with $1.00 minimum bid price rule as of Feb 26, 2024.","Pamela Palmer remains Chief Medical Officer; focus on Niyad registrational study."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":42552519.893850654,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}